Stockreport

CG Oncology Announces Nature Medicine Publication of Final Results from CORE-001 Study of Cretostimogene Grenadenorepvec in Combination with Pembrolizumab in BCG-Unresponsive NMIBC

CG Oncology, Inc.  (CGON) 
PDF – Final positive CORE-001 safety and efficacy findings were published simultaneously online by Nature Medicine and featured at ASCO 2024 – – 54% complete response (CR) [Read more]